Currently, there are 118.22M common shares owned by the public and among those 105.97M shares have been available to trade.
The company’s stock has a 5-day price change of -3.45% and 15.95% over the past three months. PRVA shares are trading -12.55% year to date (YTD), with the 12-month market performance down to -24.93% lower. It has a 12-month low price of $15.92 and touched a high of $27.14 over the same period. PRVA has an average intraday trading volume of 700.25K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.66%, 6.35%, and 1.34% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Privia Health Group Inc (NASDAQ: PRVA) shares accounts for 94.83% of the company’s 118.22M shares outstanding.
It has a market capitalization of $2.41B and a beta (3y monthly) value of 0.78. The stock’s trailing 12-month PE ratio is 168.68, while the earnings-per-share (ttm) stands at $0.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.04% over the week and 3.87% over the month.
Earnings per share for the fiscal year are expected to decrease by -22.22%, and 62.84% over the next financial year.
Looking at the support for the PRVA, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on May 30, 2024, with the firm’s price target at $23. Citigroup coverage for the Privia Health Group Inc (PRVA) stock in a research note released on April 22, 2024 offered a Buy rating with a price target of $25. Barclays was of a view on March 06, 2024 that the stock is Equal Weight, while Jefferies gave the stock Buy rating on February 26, 2024, issuing a price target of $33- $25. BofA Securities on their part issued Neutral rating on February 22, 2024.
